Last edition
News about "Manufacturing and Market Risks Mount as Scorpion C"
Manufacturing and Market Risks Mount as Scorpion Capital Bets Against Soleno's PWS Therapy
The hedge fund cited issues with Vykat XR, Soleno’s recently approved treatment for Prader-Willi syndrome, citing risks of fluid accumulation in the lungs and potential heart failure. Scorpion also suggested that the drug could eventually be withdrawn from the market.
Manufacturing And Market Risks Mount As Scorpion C | 17/08/2025 | By Darshana | 218
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members